<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Obes</journal-id><journal-id journal-id-type="iso-abbrev">J Obes</journal-id><journal-id journal-id-type="publisher-id">JOBES</journal-id><journal-title-group><journal-title>Journal of Obesity</journal-title></journal-title-group><issn pub-type="ppub">2090-0708</issn><issn pub-type="epub">2090-0716</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24303210</article-id><article-id pub-id-type="pmc">3835778</article-id><article-id pub-id-type="doi">10.1155/2013/361781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thomsen</surname><given-names>Stine Brinkl&#x000f8;v</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Rathcke</surname><given-names>Camilla Noelle</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>Nils Bruun</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5017-1815</contrib-id><name><surname>Madsbad</surname><given-names>Sten</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3090-269X</contrib-id><name><surname>Vestergaard</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, 2100 Copenhagen, Denmark</aff><aff id="I2"><sup>2</sup>Department of Medicine, Center of Endocrinology and Metabolism, Copenhagen University Hospital Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark</aff><aff id="I3"><sup>3</sup>Department of Internal Medicine, Amager Hospital, Italiensvej 1, 2300 Copenhagen, Denmark</aff><aff id="I4"><sup>4</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, 2100 Copenhagen, Denmark</aff><aff id="I5"><sup>5</sup>Department of Endocrinology, Hvidovre Hospital, Ketteg&#x000e5;rd Alle 30, 2650 Hvidovre, Denmark</aff><author-notes><corresp id="cor1">*Stine Brinkl&#x000f8;v Thomsen: <email>stine.thomsen@sund.ku.dk</email></corresp><fn fn-type="other"><p>Academic Editor: Aimin Xu</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>3</day><month>11</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>361781</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2013</year></date><date date-type="rev-recd"><day>9</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Stine Brinkl&#x000f8;v Thomsen et al.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Background</italic>. The inflammatory markers YKL-40 and monocyte chemoattractant protein-1 (MCP-1) are elevated in morbidly obese patients and decline after weight loss. The objective of our study was to investigate the possible changes of YKL-40 and MCP-1, in both the fasting and the postprandial states, following Roux-en-Y gastric bypass (RYGB) in subjects with type 2 diabetes (T2D) and normal glucose tolerance (NGT). <italic>Methods</italic>. Ten obese patients with T2D and 10 subjects with NGT were examined in the fasting state and after a standard meal prior to and after (1 week, 3 months, and 1 year) RYGB. <italic>Results</italic>. Fasting state MCP-1 levels decreased after RYGB in both groups (<italic>P</italic> values &#x0003c; 0.0001) whereas fasting YKL-40 levels were unchanged (<italic>P</italic> values &#x02265; 0.120). Postprandial MCP-1 levels showed a tendency towards a decrease on most study days; however, the changes were only significant at 1 week (<italic>P</italic> = 0.001) and 1&#x02009;yr (<italic>P</italic> &#x0003c; 0.0001) in the T2D group and at 3&#x02009;mo after RYGB in the NGT group (<italic>P</italic> = 0.009). YKL-40 levels showed a slight, postprandial suppression on all study days in the T2D group (all <italic>P</italic> values &#x02264; 0.021). <italic>Conclusions</italic>. Fasting MCP-1 levels, but not YKL-40 levels, decrease after RYGB in subjects with T2D and NGT. Postprandial changes of inflammatory markers are discrete and inconsistent.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Obesity is an increasing problem worldwide, and especially visceral obesity is strongly linked to the risk of type 2 diabetes and cardiovascular disease (CVD) [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>]. All of these conditions are characterized by a state of low-grade inflammation with elevated levels of proinflammatory cytokines and acute-phase reactants [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. It has previously been demonstrated that the intake of a high-fat diet causes elevated levels of bacterial lipopolysaccharide (LPS) in humans [<xref ref-type="bibr" rid="B6">6</xref>], which, in turn, trigger the secretion of pro-inflammatory cytokines [<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, continuously elevated levels of LPS lead to body weight gain and diabetes in mouse models, possibly through the activation of the LPS receptor CD14 and the subsequent modulation of metabolism [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The glycoprotein YKL-40, also named chitinase-3-like-1 (<italic>CHI3L1</italic>), is an inflammatory marker, found to be elevated in conditions characterized by low-grade inflammation, such as myocardial infarction [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>], and stable coronary artery disease [<xref ref-type="bibr" rid="B11">11</xref>], type 2 diabetes [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>], and morbid obesity [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. In patients with stable coronary artery disease, YKL-40 is correlated positively with triglyceride [<xref ref-type="bibr" rid="B16">16</xref>], and in type 2 diabetes patients, YKL-40 correlates positively with triglyceride and free fatty acid (FFA) levels [<xref ref-type="bibr" rid="B13">13</xref>]. </p><p>Monocyte chemoattractant protein-1 (MCP-1 or CCL-2) is a member of the CC chemokine subfamily, known to recruit cells of the immune system to the peripheral tissues during infection, injury, and other inflammatory conditions [<xref ref-type="bibr" rid="B17">17</xref>]. MCP-1 is thought to play a role in the development of inflammation and insulin resistance (IR) in obese mouse models [<xref ref-type="bibr" rid="B18">18</xref>] and may be important to the atherogenic process [<xref ref-type="bibr" rid="B19">19</xref>]. A strong association between MCP-1 and other inflammatory mediators has previously been demonstrated [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. </p><p>Roux-en-Y gastric bypass (RYGB) leads to a mean weight loss of more than 50% of the excess body weight [<xref ref-type="bibr" rid="B20">20</xref>]. Furthermore, RYGB is more effective in treating type 2 diabetes than conventional medical therapy, and in many patients, improvement in glucose metabolism occurs just days after surgery, before a major weight loss has occurred [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>]. These early changes in glucose metabolism are associated with improved hepatic IR and improved beta-cell function, while peripheral IR improves as patients lose weight [<xref ref-type="bibr" rid="B23">23</xref>&#x02013;<xref ref-type="bibr" rid="B25">25</xref>]. To our knowledge, previous studies have focused solely on the effect of RYGB on fasting levels of inflammatory markers, and levels of several inflammatory mediators, including C-reactive protein [<xref ref-type="bibr" rid="B26">26</xref>], MCP-1 [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>], and YKL-40 [<xref ref-type="bibr" rid="B14">14</xref>], have been shown to decrease after weight loss. Monte et al. recently documented that RYGB reduces the fasting plasma levels of LPS and other pro-inflammatory mediators in type 2 diabetes, and it is plausible that this reduction in the inflammatory state is responsible, at least in part, for the improvement of the glucose metabolism [<xref ref-type="bibr" rid="B27">27</xref>]. However, the decrease of inflammatory markers observed after RYGB-induced weight loss could also originate from the natural discontinuation of an excessive food intake caused by the operation [<xref ref-type="bibr" rid="B27">27</xref>], and thus it would be interesting to observe the postprandial effect on the inflammatory response after bariatric surgery.</p><p>In this study, therefore, we investigated the changes in serum levels of the inflammatory markers YKL-40 and MCP-1 in the fasting state and during mixed meal tests in a group of obese patients with type 2 diabetes and a group of obese subjects with normal glucose tolerance (NGT), previous to and after (1 week (wk), 3 months (mo), and 1 year (yr)) RYGB. We hypothesized that the presurgery &#x0201c;inflammatory load&#x0201d; would differ between the two study groups, with higher levels of inflammatory markers in the type 2 diabetes group, and that these levels would decrease in both groups after RYGB. We speculate if the possible differences between the two groups would eventually equalize as an expression of a &#x0201c;normalisation&#x0201d; of the inflammatory state, or if the type 2 diabetes group would permanently have a higher degree of inflammation. Furthermore, we wished to investigate whether the mixed meal tests would induce a temporary inflammatory response with increasing levels of the inflammatory markers, and whether this response would attenuate after RYGB. This study could add to the current knowledge of low-grade inflammation in obesity and type 2 diabetes and of the changes in weight and metabolism caused by bariatric surgery, and, furthermore, it will be a basis for further studies regarding the impact of bariatric surgery on the possible postprandial inflammatory response measured by YKL-40 and MCP-1. This can ultimately be of great importance to clinicians selecting patients to undergo bariatric surgery.</p></sec><sec id="sec2"><title>2. Material and Methods</title><sec id="sec2.1"><title>2.1. Study Design</title><p>Study population and study design have been described previously [<xref ref-type="bibr" rid="B23">23</xref>]. Study subjects with type 2 diabetes or NGT were recruited from the Hvidovre Hospital Bariatric surgery program (Hvidovre, Denmark). They all met the Danish criteria for bariatric surgery: &#x0003e;20 years of age and a body mass index (BMI) &#x0003e;40&#x02009;kg/m&#x000b2; or &#x0003e;35&#x02009;kg/m&#x000b2; with comorbidities. </p><p>NGT was defined at the time of entry into the bariatric surgery programme as fasting plasma glucose &#x0003c;6.1&#x02009;mM and 2&#x02009;h plasma glucose of &#x0003c;7.8&#x02009;mM after a 75&#x02009;g oral glucose load. Type 2 diabetes was defined as (1) treatment with &#x02265;1 antidiabetic agent(s) and a fasting plasma glucose of&#x02009;&#x02009;&#x0003e;7.0&#x02009;mM on the first study day, prior to the operation; or (2) in diet- treated subjects, a confirmatory oral glucose tolerance test was performed two weeks before surgery (2&#x02009;h plasma glucose of &#x02265;11.1&#x02009;mM). Exclusion criteria were treatment with thyroid hormone substitution therapies, antithyroid medication or anorectics, and incretin-based therapies or insulin within 3 months prior to the first study day. Subjects were studied approximately 3 days prior to (pre) and 1&#x02009;wk, 3&#x02009;mo, and 1&#x02009;yr after surgery. After the entry into the bariatric surgery programme, but prior to inclusion in the present study and the operation, all study subjects had accomplished a diet-induced weight loss of 8% of their total body weight. </p><p> Antidiabetic medications were paused 72&#x02009;h before the preoperative meal test. On each study day, preceded by a 10-hour overnight fast, anthropometric measures were retrieved, including weight (Tanita Corp., Japan), height, abdominal and hip circumference, and blood pressure (A &#x00026; D Co., Ltd., Saitama, Japan). BMI (kg/m<sup>2</sup>) and waist-hip ratio (WHR, waist circumference/hip circumference) were calculated. The participants were given a liquid meal consisting of 200&#x02009;mL of Fresubin Energy Drink (300&#x02009;kcal, carbohydrate (E% 50), protein (E%15), fat (E% 35), Fresenius Kabi Deutschland, Bad Homburg, Germany). Blood samples were obtained at meal start and frequently during the meal (0, 30, 45, 60, 90, 120, 180, and 240 minutes relative to meal start). During each meal test, the participants sat in a reclined position; no strenuous activity was allowed.</p></sec><sec id="sec2.2"><title>2.2. Surgical Procedure</title><p>Surgery was performed at the Department of Gastroenterology at Hvidovre Hospital (Hvidovre, Denmark) by either of two surgeons (L. Naver or L. Hvolris, both consultants in gastrosurgery and with expertise in RYGB), using a standard laparoscopic RYGB technique [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec id="sec2.3"><title>2.3. Laboratory Analyses</title><p>Serum insulin and C-peptide levels were measured by AutoDELFIA fluoroimmunoassay (Wallac OY, Turku, Finland). HbA1c was determined using HPLC with a cation exchange column (Tosoh Bioscience, Tokyo, Japan), and plasma glucose was measured with the glucose oxidase technique (YSI model 2300 STAT Plus; Yellow Springs Instruments, Yellow Springs, OH, USA). Plasma FFA and triglyceride concentrations were determined using commercial <italic>in vitro</italic> enzymatic calorimetric assays (Wako Chemicals Gmbh, Neuss, Germany and Roche Diagnostics Gmbh, Mannheim, Germany, resp.). Serum YKL-40 was analysed using a commercial ELISA assay (Quidel, USA), with a measuring range of 20&#x02013;300&#x02009;ng/mL, and intra- and interassay coefficients of variation (CV) of 5.8% and 6.0%, respectively. Serum MCP-1 was measured using a Bio-Plex Pro Human Cytokine MCP-1 assay (Bio-Rad, USA) with a measuring range of 2.1&#x02013;1820&#x02009;pg/mL, assay sensitivity of 1.1&#x02009;pg/mL, and intra- and interassay CV of 9% and 7%, respectively.</p></sec><sec id="sec2.4"><title>2.4. Statistical Analyses</title><p>Analyses were performed using the statistical software package SPSS 20.0 (SPSS Inc., Chicago, IL, USA). A two-sided <italic>P</italic> value &#x0003c; 0.05 was considered statistically significant. Continuous variables were presented as mean (standard deviation (SD)) or median (interquartile range (IQR)). Categorical variables were presented as numbers (%). Non-Gaussian distributed data as revealed by P-plot was logarithmically transformed using the natural logarithm prior to further parametric statistical analyses. </p><p>Baseline characteristics were presented according to status (type 2 diabetes/NGT) and study day (pre, 1&#x02009;wk, 3&#x02009;mo, and 1&#x02009;yr) (<xref ref-type="table" rid="tab1">Table 1</xref>). Categorical data were compared using the Pearson chi-square test and continuous data were compared between groups (type 2 diabetes/NGT) by Independent-Samples <italic>t</italic>-test. To assess the possible effect of RYGB on baseline characteristics, values were compared over time (pre, 1&#x02009;wk, 3&#x02009;mo, 1&#x02009;yr) between the two groups (type 2 diabetes/NGT) and within each group using repeated measures in a general linear model, with correction by Greenhouse-Geisser if Mauchly's test of sphericity proved to be significant. </p><p>To assess the effect of the mixed meal tests on the inflammatory markers (YKL-40, MCP-1) and lipids (triglyceride, FFA), repeated measures were used in a similar way, comparing the values at 0, 30, 45, 60, 90, 120, 180, and 240 minutes relative to meal start within each group on each study day. To assess the possible effect of RYGB on the postprandial inflammatory response, the total area under the curve (T-AUC) was calculated using the trapezoidal model. Incremental AUC (I-AUC) was calculated as T-AUC minus baseline &#x000d7; 4 hours (median values and interquartile range (IQR) are displayed in <xref ref-type="table" rid="tab2">Table 2</xref>). Wilcoxon matched-pairs signed-rank test was used for comparing I-AUC within groups, and for comparison between groups the Mann-Whitney <italic>U</italic>-test was used. Values missing from the mixed meal data set were calculated from previous values using the mean percentage change from the remaining study subjects. </p><p>Age and gender adjusted linear regression analyses were performed for preoperative and 1&#x02009;yr fasting values of YKL-40 and MCP-1 to investigate the possible association with the following variables: BMI, WHR, triglyceride, FFA, HbA1c, glucose, insulin, and IR. Furthermore, analyses of the possible correlation between YKL-40 and MCP-1 were made. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to calculate IR (Insulin<sub>fasting</sub> &#x000d7; glucose<sub>fasting</sub>/(22.5 &#x000d7; 6.945)).</p><p>Figures were created using R 2.15.2 statistical software package (R Foundation for Statistical Computing, Vienna, Austria). Values are mean &#x000b1; standard error of the mean (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="sec2.5"><title>2.5. Ethics Statement</title><p> All study subjects gave written informed consent, and the study was approved by the local ethics committee in accordance with the Helsinki-II declaration and by the Danish Data Protection Agency and was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</ext-link> (ClinicalTrials.gov ID <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/results?term=NCT00810823&#x00026;Search=Search">NCT00810823</ext-link>).</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Subjects</title><p>In total, 10 obese patients with type 2 diabetes and 10 obese subjects with NGT were included in the study and examined before and after RYGB (age: type 2 diabetes, 49.9 (range 37&#x02013;62) versus NGT, 42.4 (range 21&#x02013;64) yrs, <italic>P</italic> = 0.215; gender (male/female): type 2 diabetes, 4/6 versus NGT, 3/7, <italic>P</italic> = 0.369). One subject with type 2 diabetes could not be studied 1 wk after RYGB because of anaemia. One subject with NGT was excluded from the 3&#x02009;mo follow-up data set due to excessively high fasting insulin and C-peptide concentrations, indicating a nonfasting state.</p><p>At the time of inclusion, nine subjects with type 2 diabetes were treated with &#x02265;1 oral antidiabetic medication, and one subject was diet treated only. The mean time from diagnosis of type 2 diabetes was 4.5 (SD 3.6) years. After surgery, none of the patients with type 2 diabetes received any antidiabetic medication. More patients in the type 2 diabetes group had comorbidities (type 2 diabetes/NGT): hypertension: 5/5; hypercholesterolemia: 3/1; atrial fibrillation&#x02009;:&#x02009;1/0; angina pectoris: 1/0; stroke&#x02009;:&#x02009;1/0; microalbuminuria: 2/0; arthritis: 2/0. After one year, only one subject out of 5 in the NGT group received antihypertensive medication, whereas the number was 4 out of 5 in the type 2 diabetes group. All study subjects were offered pain medication (ibumetin, 400&#x02009;mg &#x000d7; 3/day) after surgery, that is, the 1&#x02009;wk study day.</p></sec><sec id="sec3.2"><title>3.2. Clinical Characteristics, Biometrics, and Blood Pressure</title><p>Data are presented in <xref ref-type="table" rid="tab1">Table 1</xref>. Both groups lost weight after RYGB; after 1&#x02009;yr subjects had lost about 25% of their preoperative body weight (type 2 diabetes: 1&#x02009;wk: 1.8 (SD 1.4) %; 3&#x02009;mo: 13.7 (SD 3.8) %; 1&#x02009;yr: 23.7 (SD 9.2) %; NGT: 1&#x02009;wk: 2.4 (SD 1.4) %; 3&#x02009;mo: 14.6 (SD 4.9) %; 1&#x02009;yr: 24.7 (SD 8.2) %, <italic>P</italic> &#x0003c; 0.0001 for both). </p><p>BMI and WHR did not differ between the groups prior to the operation or at any time point after RYGB (all <italic>P</italic> values &#x02265; 0.483). There was a significant decrease in BMI over time within both groups (type 2 diabetes: 42.5 (SD 5.7) kg/m<sup>2</sup> &#x02212;32.8 (SD 8.2) kg/m<sup>2</sup>; NGT: 42.5 (SD 4.6) kg/m<sup>2</sup> &#x02212;32.1 (SD 4.4) kg/m<sup>2</sup>, <italic>P</italic> values &#x0003c; 0.0001 for both), but with no overall difference between the groups (<italic>P</italic> = 0.738). WHR changed significantly in both groups (type 2 diabetes: <italic>P</italic> = 0.030; NGT: <italic>P</italic> = 0.017), but no differences were seen between the groups (<italic>P</italic> = 0.589). Systolic blood pressure did not change in the type 2 diabetes group (pre, 136 (SD 15) mmHg; 1&#x02009;wk, 131 (SD 13) mmHg; 3&#x02009;mo, 134 (10) mmHg; 1&#x02009;yr, 138 (12) mmHg, <italic>P</italic> = 0.517). In the NGT group, there was a tendency towards a decrease of the systolic blood pressure; however, this was not significant (pre, 135 (SD 6) mmHg; 1&#x02009;wk, 136 (SD 12) mmHg; 3&#x02009;mo, 136 (SD 12) mmHg; 1&#x02009;yr, 130 (SD 14) mmHg, <italic>P</italic> = 0.411). The diastolic blood pressure did not change in the type 2 diabetes group (pre, 83 (SD 7) mmHg; 1&#x02009;wk, 79 (SD 8) mmHg; 3&#x02009;mo, 81 (SD 7) mmHg; 1&#x02009;yr, 83 (SD 9) mmHg, <italic>P</italic> = 0.512); however, in the NGT group, there was a significant decrease (pre, 81 (SD 11) mmHg; 1&#x02009;wk, 75 (SD 9) mmHg; 3&#x02009;mo, 78 (SD 6) mmHg; 1&#x02009;yr, 73 (SD 9) mmHg, <italic>P</italic> = 0.010). Diastolic blood pressure differed between the groups at 1&#x02009;yr (<italic>P</italic> = 0.036); however, no other differences of blood pressure between groups were observed (<italic>P</italic> values &#x02265; 0.214).</p></sec><sec id="sec3.3"><title>3.3. Fasting State</title><p>Data are presented in <xref ref-type="table" rid="tab1">Table 1</xref>. Triglycerides decreased after RYGB in both groups (<italic>P</italic> values &#x02264; 0.017 for both), and FFA decreased in the type 2 diabetes group (<italic>P</italic> &#x0003c; 0.0001) but only showed a tendency towards a decrease in the NGT group (<italic>P</italic> = 0.087). There were no differences between the two groups at any study day (all <italic>P</italic> values &#x02265; 0.162). YKL-40 levels did not change significantly over time within either group (<italic>P</italic> values &#x02265; 0.120 for both), and there were no differences between the groups at any time point (all <italic>P</italic> values &#x02265; 0.156). MCP-1 levels decreased over time in both groups (<italic>P</italic> &#x0003c; 0.0001 for both), but with no significant differences between the two groups at any time-point (all <italic>P</italic> values &#x02265; 0.333).</p><p>Plasma values of glucose and HbA1c and serum values of insulin and C-peptide are presented in the Supplementary Table S1 available online at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2013/361781">http://dx.doi.org/10.1155/2013/361781</ext-link>. </p></sec><sec id="sec3.4"><title>3.4. Postprandial State</title><p>Changes in postprandial levels of inflammatory markers and lipids are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, and median I-AUC YKL-40 levels are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. YKL-40 showed a pattern of a small postprandial decrease followed by an increase on all study days for the type 2 diabetes group (<italic>P</italic> values &#x02264; 0.021 for all) and at 1&#x02009;wk for the NGT group (<italic>P</italic> = 0.038), whereas the changes before the operation and at 3&#x02009;mo and 1&#x02009;yr were nonsignificant (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>). I-AUC YKL-40 levels increased significantly for the type 2 diabetes group at 1&#x02009;wk and 1&#x02009;yr compared to baseline (pre: &#x02212;31.38 (IQR &#x02212;56.00; &#x02212;13.72) <italic>&#x003bc;</italic>g/L/t; 1&#x02009;wk: 5.25 (IQR &#x02212;10.56; 12.25) <italic>&#x003bc;</italic>g/L/t, <italic>P</italic> = 0.008; 1&#x02009;yr: &#x02212;0.75 (IQR &#x02212;12.56; 13.94) <italic>&#x003bc;</italic>g/L/t, <italic>P</italic> = 0.007). There were no significant changes of I-AUC YKL-40 levels in the NGT group. I-AUC YKL-40 levels only differed significantly between the groups at 3&#x02009;mo (type 2 diabetes: &#x02212;27.56 (IQR &#x02212;64.90; &#x02212;18.00) <italic>&#x003bc;</italic>g/L/t; NGT: &#x02212;15.38 (IQR &#x02212;20.31; 5.56) <italic>&#x003bc;</italic>g/L/t, <italic>P</italic> = 0.022) (<xref ref-type="table" rid="tab2">Table 2</xref>). </p><p>Generally, MCP-1 levels showed a tendency towards a small postprandial decrease on most study days; however, these changes were only significant for the type 2 diabetes group at 1&#x02009;wk (<italic>P</italic> = 0.001) and 1&#x02009;yr (<italic>P</italic> &#x0003c; 0.0001) and for the NGT group at 3&#x02009;mo (<italic>P</italic> = 0.009) (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). I-AUC MCP-1 levels did not change significantly after RYGB (all <italic>P</italic> values &#x02265; 0.093), nor were there any differences between the groups on any study day (all <italic>P</italic> values &#x02265; 0.121) (<xref ref-type="table" rid="tab2">Table 2</xref>). </p><p>Postprandial levels of plasma triglyceride increased in both groups before the operation (<italic>P</italic> values &#x0003c; 0.0001 for both) and at 3&#x02009;mo (<italic>P</italic> values 0.023&#x02013;0.048), and for the type 2 diabetes group there was also a significant increase at 1 yr (<italic>P</italic> = 0.020) (<xref ref-type="fig" rid="fig1">Figure 1(c)</xref>). I-AUC-levels of triglyceride decreased significantly at 1&#x02009;wk and 3&#x02009;mo compared to baseline for both groups (Type 2 diabetes: pre: 0.91 (IQR 0.26; 1.58) mmol/L/t; 1&#x02009;wk: 0.11 (IQR&#x02212;0.18; 0.45) mmol/L/t, <italic>P</italic> = 0.028; 3&#x02009;mo: 0.18 (IQR -0.06; 0.49) mmol/L/t, <italic>P</italic> = 0.013; NGT: pre: 0.92 (IQR 0.55; 1.52) mmol/L/t; 1&#x02009;wk: 0.05 (IQR&#x02212;0.23; 0.22) mmol/L/t, <italic>P</italic> = 0.007; 3&#x02009;mo: 0.31 (IQR 0.10; 0.59) mmol/L/t, <italic>P</italic> = 0.011). No differences were observed between the groups (all <italic>P</italic> values &#x02265; 0.306) (<xref ref-type="table" rid="tab2">Table 2</xref>). </p><p>Postprandial levels of FFA showed the same pattern for both groups on all study days, a decrease followed by an increase (all <italic>P</italic> values &#x0003c; 0.0001) (<xref ref-type="fig" rid="fig1">Figure 1(d)</xref>). I-AUC FFA levels did not change significantly after RYGB in either of the groups (all <italic>P</italic> values &#x02265;0.203), nor were there any differences between the groups (all <italic>P</italic> values &#x02265; 0.151) (<xref ref-type="table" rid="tab2">Table 2</xref>). </p></sec><sec id="sec3.5"><title>3.5. Correlations of YKL-40 and MCP-1 with BMI, WHR, Lipids, and Glucose Metabolites</title><p> Neither YKL-40 nor MCP-1 correlated significantly with BMI, WHR, triglyceride, FFA, HbA1c, or HOMA-IR preoperatively (type 2 diabetes: <italic>P</italic> values = 0.063 &#x02212; 0.996; NGT: <italic>P</italic> values = 0.063 &#x02212; 0.944) or at 1&#x02009;yr after the operation (type 2 diabetes: <italic>P</italic> values = 0.160 &#x02212; 0.980; NGT: <italic>P</italic> values 0.081 &#x02212; 0.916) in gender and age adjusted linear regression models when adjusting a.m. Bonferroni. </p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>This is the first study to investigate the effects of RYGB on fasting levels as well as postprandial changes of lipids and the inflammatory markers YKL-40 and MCP-1 in obese patients with type 2 diabetes and matched NGT subject. We found that fasting levels of MCP-1 decreased after surgically induced weight loss in patients with type 2 diabetes and in participants with NGT (<italic>P</italic> &#x0003c; 0.0001 for both); however, no changes of YKL-40 fasting levels were found in either study group after RYGB. Postprandial changes of the two inflammatory markers were not, as expected, a temporary postprandial increase. On the contrary, a tendency towards decreasing postprandial MCP-1 levels in both study groups on most study days was observed, whereas postprandial changes of YKL-40 followed the same pattern on all study days in the type 2 diabetes group with a small decrease followed by an almost even-sized increase. No correlations between YKL-40 and MCP-1 or between the inflammatory markers and markers of obesity and type 2 diabetes or cardiovascular risk factors could be documented. </p><p>Previously, it has been documented that plasma levels of YKL-40 are increased in obese patients with type 2 diabetes [<xref ref-type="bibr" rid="B12">12</xref>] compared to obese with NGT [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. However, we could not document a higher inflammatory burden as measured by YKL-40 and MCP-1 levels among type 2 diabetes patients compared to otherwise healthy obese subjects, perhaps explained by the severe obesity in both groups, which may have been the main contributor to the inflammation compared with type 2 diabetes per se. </p><p>This is contrary to the findings of Catal&#x000e1;n et al. [<xref ref-type="bibr" rid="B15">15</xref>], where the study population of obese patients with type 2 diabetes and obese subjects with NGT had a BMI similar to our study subjects (type 2 diabetes 47.0 &#x000b1; 2.4 (SEM) kg/m<sup>2</sup>; NGT 44.0 &#x000b1; 1.3 (SEM) kg/m<sup>2</sup>), but where the presurgical YKL-40 levels differed significantly between the groups. In this, however, the mean values of circulating YKL-40 in healthy lean subjects (18.9 &#x000b1; 5.3 (SEM) ng/mL) and in obese subjects with NGT (approximately 24&#x02009;ng/mL) were rather low compared to other studies regarding obesity [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B14">14</xref>] and also compared to studies regarding YKL-40 levels in healthy subjects [<xref ref-type="bibr" rid="B29">29</xref>] and in the general population [<xref ref-type="bibr" rid="B30">30</xref>]. However, even though YKL-40 levels have been shown to increase with age, no differences between genders have been observed [<xref ref-type="bibr" rid="B31">31</xref>], and no normal range of YKL-40 in healthy individuals has yet been established [<xref ref-type="bibr" rid="B32">32</xref>]. Furthermore, it is difficult to draw direct comparison between studies, since some studies use serum values [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>] and others use plasma values of YKL-40 [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. Also, differences due to the use of different immuno assays have to be considered [<xref ref-type="bibr" rid="B32">32</xref>]. The infiltration of white adipose tissue by macrophages and the following expression of inflammatory molecules by activated macrophages and adipocytes are thought to contribute to the systemic inflammation seen in obesity [<xref ref-type="bibr" rid="B4">4</xref>], in turn, leading to the development of IR and type 2 diabetes [<xref ref-type="bibr" rid="B33">33</xref>]. Thus, the &#x0201c;inflammatory profile&#x0201d; in morbidly obese type 2 diabetes patients without any major complications compared to obese with NGT may not differ at large. Another explanation could be that all of the subjects in this study lost 8% of their body weight prior to the operation and inclusion in the present study, and that any major differences between the two groups had therefore already equalized.</p><p>As it was the case in this study, fasting MCP-1 levels have previously been shown to decrease markedly after bariatric surgery in both type 2 diabetes [<xref ref-type="bibr" rid="B27">27</xref>] and subjects with different degrees of IR [<xref ref-type="bibr" rid="B28">28</xref>]. MCP-1 is known to be expressed in atherosclerotic plaques <italic>in vivo </italic>[<xref ref-type="bibr" rid="B34">34</xref>], and plasma protein levels of MCP-1 above the 75 percentile have been shown to be associated with all-cause death or myocardial infarction in a large group of patients with acute coronary syndrome [<xref ref-type="bibr" rid="B35">35</xref>]. MCP-1 has been shown to increase with age in a healthy elderly population, whereas no gender diffences were observed [<xref ref-type="bibr" rid="B36">36</xref>]. Mouse models have shown that the expression of an MCP-1 transgene in adipose tissue induces infiltration of macrophages into the adipose tissue and promotes the development of IR and that the inhibition of MCP-1 can reduce the infiltration of macrophages and the degree of IR in obese mice [<xref ref-type="bibr" rid="B18">18</xref>]. It is thus plausible that MCP-1 is an important link between inflammation and the development of obesity related conditions such as CVD and type 2 diabetes [<xref ref-type="bibr" rid="B37">37</xref>]. </p><p>YKL-40 is considered a marker of inflammation and endothelial dysfunction, and elevated levels are found in patients with acute and stable CVD [<xref ref-type="bibr" rid="B32">32</xref>]. YKL-40 is secreted by a variety of cells with relations to the innate immune system [<xref ref-type="bibr" rid="B32">32</xref>] and is thought to facilitate the formation of lipid laden macrophages in the vascular cell wall [<xref ref-type="bibr" rid="B38">38</xref>], which is an important step in the formation of the atherosclerotic plaque. Previously, elevated levels of fasting serum YKL-40 in morbidly obese subjects have been documented to decrease after bariatric surgery [<xref ref-type="bibr" rid="B14">14</xref>]. However, we did not find a decrease in circulating YKL-40 levels following RYGB, which is in accordance with another study by Catal&#x000e1;n et al., where a decrease of YKL-40 levels was found only after diet-induced and not surgically induced weight loss [<xref ref-type="bibr" rid="B15">15</xref>]. Even though we did not find an association between WHR and YKL-40 levels, these two variables have previously been shown to be closely correlated [<xref ref-type="bibr" rid="B15">15</xref>]. We did see a decrease of WHR; however, the volume of visceral fat may not have been reduced sufficiently to cause decreased levels of YKL-40. Alternatively, the method of RYGB or the fact that the gastrointestinal tract changes metabolically [<xref ref-type="bibr" rid="B39">39</xref>] can be a possible explanation for the nonaltered YKL-40 levels. </p><p>The expression of MCP-1 is induced by various inflammatory mediators, including LPS [<xref ref-type="bibr" rid="B17">17</xref>]. Plasma levels of LPS and the expression of Toll-like receptor 4 (TLR4) protein in mononuclear cells have been shown to increase following a high-fat, high-carbohydrate meal (910&#x02009;kcal; 41% carbohydrate, 17% protein, 42% fat) during a 3-hour period, compared to a meal rich in fruit and fibre (910&#x02009;kcal; 58% carbohydrate, 15% protein, and 27% fat) [<xref ref-type="bibr" rid="B40">40</xref>]. Contrary to our expectations, we found that postprandial MCP-1 concentrations tended to decrease on most study days. This pattern, expressed as I-AUC MCP-1 levels, did not change after RYGB, and there were no differences between the groups. It could be speculated that the mixed meal given to our study subjects might not have contained a sufficient amount of calories (300&#x02009;kcal; 50% carbohydrate, 15% protein, and 35% fat) to induce an inflammatory response. Postprandial changes of YKL-40 were small in both groups. In the type 2 diabetes group, the general pattern was a small decrease followed by an almost even sized increase; however, I-AUC YKL-40 increased significantly at 1&#x02009;wk (<italic>P</italic> = 0.008) and 1&#x02009;yr (<italic>P</italic> = 0.007) compared to baseline, indicating an attenuation of the postprandial decrease of YKL-40. However, the postprandial changes of the inflammatory markers are discrete and could be a chance finding.</p><p>The results from previous studies show a discrepancy, since MCP-1 levels have been found to correlate positively with both BMI and IR in one study [<xref ref-type="bibr" rid="B28">28</xref>], whereas another study showed no positive correlations [<xref ref-type="bibr" rid="B35">35</xref>]. In accordance with the latter, we did not find an association between MCP-1 and BMI.</p><p>Previously, higher YKL-40 levels have been observed with higher BMI, although a positive correlation between YKL-40 and BMI in multivariate adjusted analyses has not been documented [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. We have previously speculated whether YKL-40 could induce lipolysis in adipocytes through the initiation of the mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K) signalling pathways and thereby influence the development of dyslipidemia [<xref ref-type="bibr" rid="B30">30</xref>]. In this study, however, we could not document a correlation between YKL-40 and lipids, as it has been demonstrated before [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B41">41</xref>], and decreasing fasting levels of triglycerides and FFA were observed after RYGB, whereas fasting levels of YKL-40 did not change significantly.</p><p>YKL-40 is thought to promote the release of MCP-1 and other pro-inflammatory chemokines by alveolar macrophages from COPD patients [<xref ref-type="bibr" rid="B42">42</xref>]. Thus, we would have expected a positive correlation between the two markers. However, in contrast to previous findings [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>], we did not see this association.</p><p>One of the limitations to this study is the sample size, which could explain why we did not find a significant decrease of YKL-40 after RYGB or any significant associations of YKL-40 with MCP-1, measures of obesity, lipids, or glucose metabolism. Furthermore, the fact that we did not include lean age- and gender-matched subjects for controls makes it difficult to draw conclusions regarding the putative &#x0201c;normalisation&#x0201d; of the inflammatory state in the formerly morbid obese subjects.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>We document decreasing fasting levels of MCP-1 over a one-year period after RYGB in obese subjects with type 2 diabetes and NGT, whereas fasting levels of YKL-40 did not change significantly. No difference in the inflammatory burden between type 2 diabetes and subjects with NGT was observed. Postprandial levels of MCP-1 tended towards a decrease; however, the postprandial changes of YKL-40 levels were less consistent. No correlations were found between YKL-40 and MCP-1 or between the inflammatory markers and obesity-related clinical features or lipid levels. </p></sec><sec sec-type="supplementary-material" id="supplementary-material-sec"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="f1"><caption><p>The fasting values of plasma glucose, serum insulin and C&#x02013;peptide decreased over time in both groups (P &#x02264; 0.008, for all). Fasting levels of glucose differed between groups on all study days (P &#x02264; 0.023, for all), whereas no differences regarding serum insulin and serum C&#x02013;peptide were found between the groups (P &#x02265; 0.171, for all). HbA1c decreased in the type 2 diabetes group (Pre: 53.0 (SD 9.8) mmol/mol; 3 mo: 41.6 (SD 9.9) mmol/mol; 1 yr: 37.7 (SD 6.8) mmol/mol; P = 0.001), whereas no significant change was observed in the NGT group (P = 0.161). The HbA1c- values differed between the groups prior to the operation (P &#x0003c; 0.0001) and at 3 mo (P = 0.047), but not at 1 yr (P = 0.270).</p></caption><media xlink:href="361781.f1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>Stine Brinkl&#x000f8;v Thomsen wrote the paper and researched data. Camilla Noelle Rathcke provided statistical assistance, reviewed the paper, and contributed to the discussion. Nils Bruun J&#x000f8;rgensen, Sten Madsbad, and Henrik Vestergaard reviewed the paper and contributed to the discussion. The authors declare that no conflict of interests exists. The study was supported by grants from the Research Foundation of Herlev Hospital and the Danish Medical Research Council. They thank Tobias Wirenfeldt Klausen, Department of Hematology, Herlev Hospital, University of Copenhagen, for statistical counselling and for creating the figures for this paper, and Ulla Kjaerulff-Hansen, Rikke Mirsbach Henkel, and Hanne Dorthe Mogensen, Endocrine Research Laboratory 54O4, Herlev Hospital, University of Copenhagen, for skillful laboratory assistance with measurements of YKL-40. </p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>AD</given-names></name><name><surname>Skerrett</surname><given-names>PJ</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name></person-group><article-title>Obesity, diabetes, and coronary risk in women</article-title><source><italic>Journal of Cardiovascular Risk</italic></source><year>2002</year><volume>9</volume><issue>6</issue><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="other">2-s2.0-0036927451</pub-id><pub-id pub-id-type="pmid">12478201</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Lemieux</surname><given-names>I</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>J-P</given-names></name></person-group><article-title>Visceral obesity the link among inflammation, hypertension, and cardiovascular disease</article-title><source><italic>Hypertension</italic></source><year>2009</year><volume>53</volume><issue>4</issue><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="other">2-s2.0-64849088450</pub-id><pub-id pub-id-type="pmid">19237685</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despres</surname><given-names>JP</given-names></name></person-group><article-title>Body fat distribution and risk of cardiovascular disease: an update</article-title><source><italic>Circulation</italic></source><year>2012</year><volume>126</volume><fpage>1301</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">22949540</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancello</surname><given-names>R</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>K</given-names></name></person-group><article-title>Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue</article-title><source><italic>British Journal of Obstetrics and Gynaecology</italic></source><year>2006</year><volume>113</volume><issue>10</issue><fpage>1141</fpage><lpage>1147</lpage><pub-id pub-id-type="other">2-s2.0-33748742519</pub-id><pub-id pub-id-type="pmid">16903845</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickup</surname><given-names>JC</given-names></name></person-group><article-title>Inflammatory markers and type 2 diabetes</article-title><source><italic>Diabetes Technology and Therapeutics</italic></source><year>2006</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="other">2-s2.0-33645319007</pub-id><pub-id pub-id-type="pmid">16472045</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laugerette</surname><given-names>F</given-names></name><name><surname>Vors</surname><given-names>C</given-names></name><name><surname>G&#x000e9;lo&#x000eb;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation</article-title><source><italic>Journal of Nutritional Biochemistry</italic></source><year>2011</year><volume>22</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="other">2-s2.0-78649978620</pub-id><pub-id pub-id-type="pmid">20303729</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>JC</given-names></name><name><surname>Young</surname><given-names>DW</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name><name><surname>Christ</surname><given-names>WJ</given-names></name><name><surname>Gusovsky</surname><given-names>F</given-names></name></person-group><article-title>Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>1999</year><volume>274</volume><issue>16</issue><fpage>10689</fpage><lpage>10692</lpage><pub-id pub-id-type="other">2-s2.0-0033574415</pub-id><pub-id pub-id-type="pmid">10196138</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Amar</surname><given-names>J</given-names></name><name><surname>Iglesias</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Metabolic endotoxemia initiates obesity and insulin resistance</article-title><source><italic>Diabetes</italic></source><year>2007</year><volume>56</volume><fpage>1761</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">17456850</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedegaard</surname><given-names>A</given-names></name><name><surname>Sejersten Ripa</surname><given-names>R</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>E</given-names></name><name><surname>Kastrup</surname><given-names>J</given-names></name></person-group><article-title>Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction</article-title><source><italic>Scandinavian Journal of Clinical and Laboratory Investigation</italic></source><year>2010</year><volume>70</volume><issue>2</issue><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="other">2-s2.0-77949817816</pub-id><pub-id pub-id-type="pmid">20102300</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000f8;jgaard</surname><given-names>C</given-names></name><name><surname>H&#x000f8;st</surname><given-names>NB</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Serum levels of YKL-40 increases in patients with acute myocardial infarction</article-title><source><italic>Coronary Artery Disease</italic></source><year>2008</year><volume>19</volume><issue>4</issue><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="other">2-s2.0-54749135440</pub-id><pub-id pub-id-type="pmid">18480670</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucur</surname><given-names>M</given-names></name><name><surname>Isman</surname><given-names>FK</given-names></name><name><surname>Karadag</surname><given-names>B</given-names></name><name><surname>Vural</surname><given-names>VA</given-names></name><name><surname>Tavsanoglu</surname><given-names>S</given-names></name></person-group><article-title>Serum YKL-40 levels in patients with coronary artery disease</article-title><source><italic>Coronary Artery Disease</italic></source><year>2007</year><volume>18</volume><issue>5</issue><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="other">2-s2.0-34547531506</pub-id><pub-id pub-id-type="pmid">17627189</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>AR</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Plasma YKL-40 A BMI-independent marker of type 2 diabetes</article-title><source><italic>Diabetes</italic></source><year>2008</year><volume>57</volume><issue>11</issue><fpage>3078</fpage><lpage>3082</lpage><pub-id pub-id-type="other">2-s2.0-58149352840</pub-id><pub-id pub-id-type="pmid">18650368</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><article-title>YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance</article-title><source><italic>Inflammation Research</italic></source><year>2006</year><volume>55</volume><issue>2</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="other">2-s2.0-33645815907</pub-id><pub-id pub-id-type="pmid">16612564</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempen</surname><given-names>M</given-names></name><name><surname>Kopp</surname><given-names>H-P</given-names></name><name><surname>Elhenicky</surname><given-names>M</given-names></name><etal/></person-group><article-title>YKL-40 is elevated in morbidly obese patients and declines after weight loss</article-title><source><italic>Obesity Surgery</italic></source><year>2009</year><volume>19</volume><issue>11</issue><fpage>1557</fpage><lpage>1563</lpage><pub-id pub-id-type="other">2-s2.0-70449523003</pub-id><pub-id pub-id-type="pmid">19633900</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catal&#x000e1;n</surname><given-names>V</given-names></name><name><surname>G&#x000f3;mez-Ambrosi</surname><given-names>J</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass</article-title><source><italic>Journal of Clinical Endocrinology and Metabolism</italic></source><year>2011</year><volume>96</volume><issue>1</issue><fpage>200</fpage><lpage>209</lpage><pub-id pub-id-type="other">2-s2.0-78650917241</pub-id><pub-id pub-id-type="pmid">20943784</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mygind</surname><given-names>ND</given-names></name><name><surname>Harutyunyan</surname><given-names>MJ</given-names></name><name><surname>Mathiasen</surname><given-names>AB</given-names></name><etal/></person-group><article-title>The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease</article-title><source><italic>Inflammation Research</italic></source><year>2011</year><volume>60</volume><issue>3</issue><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="other">2-s2.0-79951723231</pub-id><pub-id pub-id-type="pmid">20972697</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>A</given-names></name><name><surname>Saini</surname><given-names>V</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name></person-group><article-title>MCP-1: chemoattractant with a role beyond immunity: a review</article-title><source><italic>Clinica Chimica Acta</italic></source><year>2010</year><volume>411</volume><issue>21-22</issue><fpage>1570</fpage><lpage>1579</lpage><pub-id pub-id-type="other">2-s2.0-79955784400</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Tateya</surname><given-names>S</given-names></name><name><surname>Tamori</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>2006</year><volume>116</volume><issue>6</issue><fpage>1494</fpage><lpage>1505</lpage><pub-id pub-id-type="other">2-s2.0-33745216724</pub-id><pub-id pub-id-type="pmid">16691291</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>BA</given-names></name><name><surname>Rosenfeld</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1991</year><volume>88</volume><issue>12</issue><fpage>5252</fpage><lpage>5256</lpage><pub-id pub-id-type="other">2-s2.0-0025954705</pub-id><pub-id pub-id-type="pmid">2052604</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchwald</surname><given-names>H</given-names></name><name><surname>Estok</surname><given-names>R</given-names></name><name><surname>Fahrbach</surname><given-names>K</given-names></name><etal/></person-group><article-title>Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis</article-title><source><italic>American Journal of Medicine</italic></source><year>2009</year><volume>122</volume><issue>3</issue><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="other">2-s2.0-61549094077</pub-id><pub-id pub-id-type="pmid">19272486</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schauer</surname><given-names>PR</given-names></name><name><surname>Kashyap</surname><given-names>SR</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><etal/></person-group><article-title>Bariatric surgery versus intensive medical therapy in obese patients with diabetes</article-title><source><italic>New England Journal of Medicine</italic></source><year>2012</year><volume>366</volume><issue>17</issue><fpage>1567</fpage><lpage>1576</lpage><pub-id pub-id-type="other">2-s2.0-84860136615</pub-id><pub-id pub-id-type="pmid">22449319</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mingrone</surname><given-names>G</given-names></name><name><surname>Panunzi</surname><given-names>S</given-names></name><name><surname>De Gaetano</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bariatric surgery versus conventional medical therapy for type 2 diabetes</article-title><source><italic>New England Journal of Medicine</italic></source><year>2012</year><volume>366</volume><issue>17</issue><fpage>1577</fpage><lpage>1585</lpage><pub-id pub-id-type="other">2-s2.0-84859419232</pub-id><pub-id pub-id-type="pmid">22449317</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>NB</given-names></name><name><surname>Jacobsen</surname><given-names>SH</given-names></name><name><surname>Dirksen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance</article-title><source><italic>American Journal of Physiology: Endocrinology and Metabolism</italic></source><year>2012</year><volume>303</volume><fpage>E122</fpage><lpage>E131</lpage><pub-id pub-id-type="pmid">22535748</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Abumrad</surname><given-names>NN</given-names></name><name><surname>Breitman</surname><given-names>I</given-names></name><etal/></person-group><article-title>Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy</article-title><source><italic>Diabetes Care</italic></source><year>2012</year><volume>35</volume><issue>1</issue><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="other">2-s2.0-84859041004</pub-id><pub-id pub-id-type="pmid">22040841</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camastra</surname><given-names>S</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes</article-title><source><italic>Diabetologia</italic></source><year>2011</year><volume>54</volume><issue>8</issue><fpage>2093</fpage><lpage>2102</lpage><pub-id pub-id-type="other">2-s2.0-79960913296</pub-id><pub-id pub-id-type="pmid">21614570</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>GD</given-names></name><name><surname>Nicklas</surname><given-names>BJ</given-names></name><name><surname>Fernandez</surname><given-names>A</given-names></name></person-group><article-title>Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery</article-title><source><italic>Surgery for Obesity and Related Diseases</italic></source><year>2011</year><volume>7</volume><issue>5</issue><fpage>618</fpage><lpage>624</lpage><pub-id pub-id-type="other">2-s2.0-80053328335</pub-id><pub-id pub-id-type="pmid">21546319</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monte</surname><given-names>SV</given-names></name><name><surname>Caruana</surname><given-names>JA</given-names></name><name><surname>Ghanim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus</article-title><source><italic>Surgery</italic></source><year>2012</year><volume>151</volume><issue>4</issue><fpage>587</fpage><lpage>593</lpage><pub-id pub-id-type="other">2-s2.0-84858439217</pub-id><pub-id pub-id-type="pmid">22088821</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schernthaner</surname><given-names>G-H</given-names></name><name><surname>Kopp</surname><given-names>H-P</given-names></name><name><surname>Kriwanek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity</article-title><source><italic>Obesity Surgery</italic></source><year>2006</year><volume>16</volume><issue>6</issue><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="other">2-s2.0-33646674384</pub-id><pub-id pub-id-type="pmid">16756729</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Lottenburger</surname><given-names>T</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects</article-title><source><italic>Cancer Epidemiology Biomarkers and Prevention</italic></source><year>2008</year><volume>17</volume><issue>10</issue><fpage>2603</fpage><lpage>2608</lpage><pub-id pub-id-type="other">2-s2.0-54249128937</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>SB</given-names></name><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Skaaby</surname><given-names>T</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><article-title>The Association between genetic variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and the lipid profile in a Danish population</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><pub-id pub-id-type="publisher-id">e47094</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><article-title>YKL-40&#x02014;an emerging biomarker in cardiovascular disease and diabetes</article-title><source><italic>Cardiovascular Diabetology</italic></source><year>2009</year><volume>8, article 61</volume><pub-id pub-id-type="other">2-s2.0-71949101822</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastrup</surname><given-names>J</given-names></name></person-group><article-title>Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?</article-title><source><italic>Immunobiology</italic></source><year>2012</year><volume>217</volume><issue>5</issue><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="other">2-s2.0-84858797734</pub-id><pub-id pub-id-type="pmid">21601307</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumeng</surname><given-names>CN</given-names></name><name><surname>Saltiel</surname><given-names>AR</given-names></name></person-group><article-title>Inflammatory links between obesity and metabolic disease</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>2011</year><volume>121</volume><issue>6</issue><fpage>2111</fpage><lpage>2117</lpage><pub-id pub-id-type="other">2-s2.0-79957920754</pub-id><pub-id pub-id-type="pmid">21633179</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neiken</surname><given-names>NA</given-names></name><name><surname>Coughlin</surname><given-names>SR</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Wilcox</surname><given-names>JN</given-names></name></person-group><article-title>Monocyte chemoattractant protein-1 in human atheromatous plaques</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>1991</year><volume>88</volume><issue>4</issue><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="other">2-s2.0-0026075699</pub-id><pub-id pub-id-type="pmid">1843454</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lemos</surname><given-names>JA</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes</article-title><source><italic>Circulation</italic></source><year>2003</year><volume>107</volume><issue>5</issue><fpage>690</fpage><lpage>695</lpage><pub-id pub-id-type="other">2-s2.0-0037432168</pub-id><pub-id pub-id-type="pmid">12578870</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>E</given-names></name><name><surname>Cattini</surname><given-names>L</given-names></name><name><surname>Neri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Simultaneous evaluation of circulating chemokine and cytokine profiles in elderly subjects by multiplex technology: relationship with zinc status</article-title><source><italic>Biogerontology</italic></source><year>2006</year><volume>7</volume><issue>5-6</issue><fpage>449</fpage><lpage>459</lpage><pub-id pub-id-type="other">2-s2.0-34548499454</pub-id><pub-id pub-id-type="pmid">16967203</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rull</surname><given-names>A</given-names></name><name><surname>Camps</surname><given-names>J</given-names></name><name><surname>Alonso-Villaverde</surname><given-names>C</given-names></name><name><surname>Joven</surname><given-names>J</given-names></name></person-group><article-title>Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (orCCL2) in the regulation of metabolism</article-title><source><italic>Mediators of Inflammation</italic></source><year>2010</year><volume>2010</volume><fpage>11 pages</fpage><pub-id pub-id-type="other">2-s2.0-78349279253</pub-id><pub-id pub-id-type="publisher-id">326580</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelsen</surname><given-names>AE</given-names></name><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Skjelland</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased YKL-40 expression in patients with carotid atherosclerosis</article-title><source><italic>Atherosclerosis</italic></source><year>2010</year><volume>211</volume><issue>2</issue><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="other">2-s2.0-77955275761</pub-id><pub-id pub-id-type="pmid">20347092</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>DiBaise</surname><given-names>JK</given-names></name><name><surname>Zuccolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human gut microbiota in obesity and after gastric bypass</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2009</year><volume>106</volume><issue>7</issue><fpage>2365</fpage><lpage>2370</lpage><pub-id pub-id-type="other">2-s2.0-60549086580</pub-id><pub-id pub-id-type="pmid">19164560</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanim</surname><given-names>H</given-names></name><name><surname>Abuaysheh</surname><given-names>S</given-names></name><name><surname>Sia</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance</article-title><source><italic>Diabetes Care</italic></source><year>2009</year><volume>32</volume><issue>12</issue><fpage>2281</fpage><lpage>2287</lpage><pub-id pub-id-type="other">2-s2.0-72249106180</pub-id><pub-id pub-id-type="pmid">19755625</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaergaard</surname><given-names>AD</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group><article-title>Elevated plasma YKL-40 levels and ischemic stroke in the general population</article-title><source><italic>Annals of Neurology</italic></source><year>2010</year><volume>68</volume><issue>5</issue><fpage>672</fpage><lpage>680</lpage><pub-id pub-id-type="other">2-s2.0-78249263495</pub-id><pub-id pub-id-type="pmid">21031582</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e9;tuv&#x000e9;</surname><given-names>S</given-names></name><name><surname>Kozhich</surname><given-names>A</given-names></name><name><surname>Arouche</surname><given-names>N</given-names></name><etal/></person-group><article-title>YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages</article-title><source><italic>Journal of Immunology</italic></source><year>2008</year><volume>181</volume><issue>7</issue><fpage>5167</fpage><lpage>5173</lpage><pub-id pub-id-type="other">2-s2.0-58149308830</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p> YKL-40 (a), MCP-1 (b), triglyceride (c), and free fatty acids (FFA) (d) in response to a meal in subjects with type 2 diabetes (T2D) and with normal glucose tolerance (NGT) before (pre) and 1&#x02009;wk, 3&#x02009;mo, and 1&#x02009;yr after Roux-en-Y gastric bypass (RYGB). Data are presented as means &#x000b1; standard error of mean (SEM).</p></caption><graphic xlink:href="JOBES2013-361781.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical characteristics, lipids and inflammatory markers in subjects with type 2 diabetes, and normal glucose tolerance before (pre) and 1&#x02009;wk, 3&#x02009;mo, and 1&#x02009;yr after Roux-en-Y gastric bypass.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Pre</th><th align="center" rowspan="1" colspan="1">1&#x02009;wk</th><th align="center" rowspan="1" colspan="1">3&#x02009;mo</th><th align="center" rowspan="1" colspan="1">1&#x02009;yr</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>&#x02009;&#x02009;value<sup>&#x000a7;</sup></th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>II</sup></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">
<italic>N</italic> (% of total)</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">9 (47)</td><td align="center" rowspan="1" colspan="1">10 (53)</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">10 (53)</td><td align="center" rowspan="1" colspan="1">9 (47)</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Systolic BP, <break/>mmHg*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">136 (15)</td><td align="center" rowspan="1" colspan="1">131 (13)</td><td align="center" rowspan="1" colspan="1">134 (10)</td><td align="center" rowspan="1" colspan="1">138 (12)</td><td align="center" rowspan="1" colspan="1">0.517</td><td align="center" rowspan="1" colspan="1">0.295</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">135 (6)</td><td align="center" rowspan="1" colspan="1">136 (12)</td><td align="center" rowspan="1" colspan="1">136 (12)</td><td align="center" rowspan="1" colspan="1">130 (14)</td><td align="center" rowspan="1" colspan="1">0.411</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.876</td><td align="center" rowspan="1" colspan="1">0.432</td><td align="center" rowspan="1" colspan="1">0.788</td><td align="center" rowspan="1" colspan="1">0.214</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Diastolic BP, <break/>mmHg*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">83 (7)</td><td align="center" rowspan="1" colspan="1">79 (8)</td><td align="center" rowspan="1" colspan="1">81 (7)</td><td align="center" rowspan="1" colspan="1">83 (9)</td><td align="center" rowspan="1" colspan="1">0.512</td><td align="center" rowspan="1" colspan="1">0.117</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">81 (11)</td><td align="center" rowspan="1" colspan="1">75 (9)</td><td align="center" rowspan="1" colspan="1">78 (6)</td><td align="center" rowspan="1" colspan="1">73 (9)</td><td align="center" rowspan="1" colspan="1">
<bold>0.010</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.598</td><td align="center" rowspan="1" colspan="1">0.313</td><td align="center" rowspan="1" colspan="1">0.383</td><td align="center" rowspan="1" colspan="1">0.036</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Weight, <break/>Kg*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">125.9 (14.4)</td><td align="center" rowspan="1" colspan="1">124.5 (13.9)</td><td align="center" rowspan="1" colspan="1">109.0 (15.6)</td><td align="center" rowspan="1" colspan="1">96.9 (20.6)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">0.578</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">130.3 (10.4)</td><td align="center" rowspan="1" colspan="1">127.2 (9.6)</td><td align="center" rowspan="1" colspan="1">108.8 (7.6)</td><td align="center" rowspan="1" colspan="1">98.0 (12.1)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.441</td><td align="center" rowspan="1" colspan="1">0.628</td><td align="center" rowspan="1" colspan="1">0.972</td><td align="center" rowspan="1" colspan="1">0.886</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">BMI, <break/>Kg/m<sup>2&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">42.5 (5.7)</td><td align="center" rowspan="1" colspan="1">41.9 (6.0)</td><td align="center" rowspan="1" colspan="1">36.8 (6.1)</td><td align="center" rowspan="1" colspan="1">32.8 (8.2)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">0.738</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">42.5 (4.6)</td><td align="center" rowspan="1" colspan="1">41.4 (4.2)</td><td align="center" rowspan="1" colspan="1">35.2 (2.9)</td><td align="center" rowspan="1" colspan="1">32.1 (4.4)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.977</td><td align="center" rowspan="1" colspan="1">0.830</td><td align="center" rowspan="1" colspan="1">0.483</td><td align="center" rowspan="1" colspan="1">0.797</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">WHR*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">1.0 (0.1)</td><td align="center" rowspan="1" colspan="1">1.1 (0.1)</td><td align="center" rowspan="1" colspan="1">1.1 (0.1)</td><td align="center" rowspan="1" colspan="1">1.0 (0.1)</td><td align="center" rowspan="1" colspan="1">
<bold>0.030</bold>
</td><td align="center" rowspan="1" colspan="1">0.589</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">1.1 (0.1)</td><td align="center" rowspan="1" colspan="1">1.1 (0.1)</td><td align="center" rowspan="1" colspan="1">1.0 (0.1)</td><td align="center" rowspan="1" colspan="1">1.0 (0.1)</td><td align="center" rowspan="1" colspan="1">
<bold>0.017</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.917</td><td align="center" rowspan="1" colspan="1">0.650</td><td align="center" rowspan="1" colspan="1">0.647</td><td align="center" rowspan="1" colspan="1">0.832</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">TG, <break/>mmol/L*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">1.51 (0.36)</td><td align="center" rowspan="1" colspan="1">1.58 (0.22)</td><td align="center" rowspan="1" colspan="1">1.38 (0.45)</td><td align="center" rowspan="1" colspan="1">1.10 (0.39)</td><td align="center" rowspan="1" colspan="1">
<bold>0.017</bold>
</td><td align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">1.35 (0.46)</td><td align="center" rowspan="1" colspan="1">1.61 (0.53)</td><td align="center" rowspan="1" colspan="1">1.17 (0.44)</td><td align="center" rowspan="1" colspan="1">0.98 (0.41)</td><td align="center" rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.400</td><td align="center" rowspan="1" colspan="1">0.867</td><td align="center" rowspan="1" colspan="1">0.311</td><td align="center" rowspan="1" colspan="1">0.512</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">FFA, <break/>mmol/L*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">0.80 (0.25)</td><td align="center" rowspan="1" colspan="1">0.92 (0.22)</td><td align="center" rowspan="1" colspan="1">0.74 (0.20)</td><td align="center" rowspan="1" colspan="1">0.54 (0.12)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">0.859</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">0.73 (0.30)</td><td align="center" rowspan="1" colspan="1">0.78 (0.19)</td><td align="center" rowspan="1" colspan="1">0.70 (0.26)</td><td align="center" rowspan="1" colspan="1">0.50 (0.28)</td><td align="center" rowspan="1" colspan="1">0.087</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.587</td><td align="center" rowspan="1" colspan="1">0.162</td><td align="center" rowspan="1" colspan="1">0.710</td><td align="center" rowspan="1" colspan="1">0.690</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">YKL-40, <break/><italic>&#x000b5;</italic>g/L<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">51 (37; 88)</td><td align="center" rowspan="1" colspan="1">47 (35; 71)</td><td align="center" rowspan="1" colspan="1">62 (49; 110)</td><td align="center" rowspan="1" colspan="1">59 (35; 94)</td><td align="center" rowspan="1" colspan="1">0.120</td><td align="center" rowspan="1" colspan="1">0.362</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">43 (22; 99)</td><td align="center" rowspan="1" colspan="1">61 (31; 76)</td><td align="center" rowspan="1" colspan="1">44 (31; 88)</td><td align="center" rowspan="1" colspan="1">51 (27; 97)</td><td align="center" rowspan="1" colspan="1">0.930</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.388</td><td align="center" rowspan="1" colspan="1">0.947</td><td align="center" rowspan="1" colspan="1">0.156</td><td align="center" rowspan="1" colspan="1">0.449</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">MCP-1, <break/>pg/mL<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">25.2 (11.3; 35.5)</td><td align="center" rowspan="1" colspan="1">20.4 (9.0; 24.4)</td><td align="center" rowspan="1" colspan="1">15.9 (8.6; 19.9)</td><td align="center" rowspan="1" colspan="1">9.7 (6.4; 11.9)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">0.213</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">14.9 (12.4; 42.1)</td><td align="center" rowspan="1" colspan="1">17.8 (13.7; 34.4)</td><td align="center" rowspan="1" colspan="1">13.1 (9.2; 22.9)</td><td align="center" rowspan="1" colspan="1">11.1 (6.6; 16.1)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></td><td align="center" rowspan="1" colspan="1">0.920</td><td align="center" rowspan="1" colspan="1">0.533</td><td align="center" rowspan="1" colspan="1">0.887</td><td align="center" rowspan="1" colspan="1">0.333</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as *mean (SD), <sup>&#x02020;</sup>median (IQR), or number (%) where not specified. </p></fn><fn><p>
<sup>&#x02021;</sup>
<italic>P</italic> value for comparison of T2D and NGT; Independent Samples <italic>t</italic>-test.</p></fn><fn><p>
<sup>&#x000a7;</sup>
<italic>P</italic>-value for overall comparison between days within a group (T2D or NGT); repeated measures.</p></fn><fn><p>
<sup>II</sup>
<italic>P</italic> value for overall comparison of changes between the groups (T2D and NGT); repeated measures.</p></fn><fn><p>BMI: body mass index; DBP: diastolic blood pressure; FFA: free fatty acids; MCP-1: monocyte chemoattractant protein-1; NGT: normal glucose tolerance; SBP: systolic blood pressure; T2D: type 2 diabetes; TG: triglyceride; WHR: waist-hip ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>I-AUC values for postprandial concentrations of YKL-40, MCP-1, FFA, and triglycerides in subjects with type 2 diabetes and normal glucose tolerance before (pre) and 1&#x02009;wk, 3&#x02009;mo, and 1&#x02009;yr after Roux-en-Y gastric bypass.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Pre</th><th align="center" rowspan="1" colspan="1">1&#x02009;wk</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></th><th align="center" rowspan="1" colspan="1">3&#x02009;mo</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></th><th align="center" rowspan="1" colspan="1">1&#x02009;yr</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02021;</sup></th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">
<italic>N</italic> (% of total)</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">9 (47)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">10 (53)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">10 (53)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">9 (47)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="9" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">I-AUC YKL-40, <italic>&#x003bc;</italic>g/L/t*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">&#x02212;31.38 <break/>(&#x02212;56.0; &#x02212;13.72)</td><td align="center" rowspan="1" colspan="1">5.25 <break/> (&#x02212;10.56; 12.25)</td><td align="center" rowspan="1" colspan="1">
<bold>0.008</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02212;27.56 <break/>(&#x02212;64.90; &#x02212;18.00)</td><td align="center" rowspan="1" colspan="1">0.866</td><td align="center" rowspan="1" colspan="1">&#x02212;0.75 <break/>(&#x02212;12.56;13.94)</td><td align="center" rowspan="1" colspan="1">
<bold>0.007</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">&#x02212;18.44 <break/>(&#x02212;31.69; &#x02212;6.41)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.19 <break/>(&#x02212;16.53; 6.60)</td><td align="center" rowspan="1" colspan="1">0.386</td><td align="center" rowspan="1" colspan="1">&#x02212;15.38 <break/> (&#x02212;20.31; 5.56)</td><td align="center" rowspan="1" colspan="1">0.260</td><td align="center" rowspan="1" colspan="1">&#x02212;2.75 <break/>(&#x02212;13.35; &#x02212;17.78)</td><td align="center" rowspan="1" colspan="1">0.114</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">0.174</td><td align="center" rowspan="1" colspan="1">0.414</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.821</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="9" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">I-AUC MCP1, pg/mL/t*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">&#x02212;14.62 <break/>(&#x02212;36.38; &#x02212;0.19)</td><td align="center" rowspan="1" colspan="1">&#x02212;8.81 <break/>(&#x02212;16.58; &#x02212;2.33)</td><td align="center" rowspan="1" colspan="1">0.139</td><td align="center" rowspan="1" colspan="1">&#x02212;8.80 <break/>(&#x02212;27.02; 0.67)</td><td align="center" rowspan="1" colspan="1">0.721</td><td align="center" rowspan="1" colspan="1">&#x02212;7.65 <break/>(&#x02212;17.14; &#x02212;1.39)</td><td align="center" rowspan="1" colspan="1">0.114</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">&#x02212;7.78 <break/>(&#x02212;21.28; &#x02212;1.42)</td><td align="center" rowspan="1" colspan="1">&#x02212;7.79 <break/>(&#x02212;14.02; &#x02212;1.63)</td><td align="center" rowspan="1" colspan="1">0.445</td><td align="center" rowspan="1" colspan="1">&#x02212;1.37 <break/> (&#x02212;11.52; 21.01)</td><td align="center" rowspan="1" colspan="1">0.441</td><td align="center" rowspan="1" colspan="1">&#x02212;3.32 <break/>(&#x02212;5.69; 2.65)</td><td align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">0.705</td><td align="center" rowspan="1" colspan="1">0.935</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.121</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.226</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="9" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">I-AUC FFA, mmol/L/t*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">&#x02212;1.14 <break/>(&#x02212;1.84; &#x02212;0.61)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.82 <break/>(&#x02212;1.66; &#x02212;0.64)</td><td align="center" rowspan="1" colspan="1">0.859</td><td align="center" rowspan="1" colspan="1">&#x02212;1.16 <break/>(&#x02212;1.52; &#x02212;0.94)</td><td align="center" rowspan="1" colspan="1">0.878</td><td align="center" rowspan="1" colspan="1">&#x02212;1.16 <break/>(&#x02212;1.38; &#x02212;0.64)</td><td align="center" rowspan="1" colspan="1">0.508</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">&#x02212;0.69 <break/>(&#x02212;1.71; 0.49)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.68 <break/>(&#x02212;1.19; &#x02212;0.37)</td><td align="center" rowspan="1" colspan="1">0.333</td><td align="center" rowspan="1" colspan="1">&#x02212;1.36 <break/>(&#x02212;1.75; &#x02212;0.78)</td><td align="center" rowspan="1" colspan="1">0.441</td><td align="center" rowspan="1" colspan="1">&#x02212;0.77 <break/>(&#x02212;1.24; 0.03)</td><td align="center" rowspan="1" colspan="1">0.203</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">0.450</td><td align="center" rowspan="1" colspan="1">0.191</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.806</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.151</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="9" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">I-AUC TG, mmol/L/t*</td><td align="center" rowspan="1" colspan="1">T2D</td><td align="center" rowspan="1" colspan="1">0.91 <break/>(0.26; 1.58)</td><td align="center" rowspan="1" colspan="1">0.11 <break/>(&#x02212;0.18; 0.45)</td><td align="center" rowspan="1" colspan="1">
<bold>0.028</bold>
</td><td align="center" rowspan="1" colspan="1">0.18 <break/>(&#x02212;0.06; 0.49)</td><td align="center" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="center" rowspan="1" colspan="1">0.46 <break/>(0.03; 0.70)</td><td align="center" rowspan="1" colspan="1">0.059</td></tr><tr><td align="center" rowspan="1" colspan="1">NGT</td><td align="center" rowspan="1" colspan="1">0.92 <break/>(0.55; 1.52)</td><td align="center" rowspan="1" colspan="1">0.05 <break/>(&#x02212;0.23; 0.22)</td><td align="center" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="center" rowspan="1" colspan="1">0.31 <break/>(0.10; 0.59)</td><td align="center" rowspan="1" colspan="1">
<bold>0.011</bold>
</td><td align="center" rowspan="1" colspan="1">0.30 <break/>(0.06; 0.60)</td><td align="center" rowspan="1" colspan="1">0.074</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic>P</italic> value<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">0.762</td><td align="center" rowspan="1" colspan="1">0.306</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.414</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.677</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>*Median (IQR).</p></fn><fn><p>
<sup>&#x02020;</sup>
<italic>P</italic> value: comparison between groups (T2D/NGT). Mann-Whitney <italic>U-</italic>test.</p></fn><fn><p>
<sup>&#x02021;</sup>
<italic>P</italic> value: compared to baseline (pre). Wilcoxon matched-pairs signed-rank test.</p></fn><fn><p>I-AUC: incremental area under the curve; MCP-1: monocyte chemoattractant protein-1; FFA: free fatty acids; TG: triglycerides; T2D: type 2 diabetes; NGT: normal glucose tolerance.</p></fn></table-wrap-foot></table-wrap></floats-group></article>